MX373330B - Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. - Google Patents
Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano.Info
- Publication number
- MX373330B MX373330B MX2016005867A MX2016005867A MX373330B MX 373330 B MX373330 B MX 373330B MX 2016005867 A MX2016005867 A MX 2016005867A MX 2016005867 A MX2016005867 A MX 2016005867A MX 373330 B MX373330 B MX 373330B
- Authority
- MX
- Mexico
- Prior art keywords
- dextromethorphan
- compositions
- bupropion
- methods
- related compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En esta divulgación se describe un método para tratar un trastorno neurológico mediante la administración de un compuesto antidepresivo y dextrometorfano a un ser humano que lo necesita. Este método puede ser útil para seres humanos, los cuales son metabolizadores extensos de dextrometorfano. También se describen composiciones, medicamentos y formas de dosificación que comprenden compuestos antidepresivos y dextrometorfano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900354P | 2013-11-05 | 2013-11-05 | |
| PCT/US2014/064184 WO2015069809A1 (en) | 2013-11-05 | 2014-11-05 | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016005867A MX2016005867A (es) | 2016-07-15 |
| MX373330B true MX373330B (es) | 2020-05-04 |
Family
ID=53042051
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004075A MX388666B (es) | 2013-11-05 | 2014-11-05 | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano |
| MX2016005867A MX373330B (es) | 2013-11-05 | 2014-11-05 | Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. |
| MX2021015234A MX2021015234A (es) | 2013-11-05 | 2016-05-04 | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004075A MX388666B (es) | 2013-11-05 | 2014-11-05 | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015234A MX2021015234A (es) | 2013-11-05 | 2016-05-04 | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano. |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP3981403A1 (es) |
| JP (5) | JP6605485B2 (es) |
| KR (4) | KR20230148385A (es) |
| CN (7) | CN113750099A (es) |
| AU (7) | AU2014346807B2 (es) |
| CA (4) | CA2929415C (es) |
| IL (3) | IL298972A (es) |
| MX (3) | MX388666B (es) |
| MY (1) | MY179696A (es) |
| NZ (1) | NZ758428A (es) |
| SG (4) | SG11201603391XA (es) |
| WO (1) | WO2015069809A1 (es) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
| US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
| US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20220233470A1 (en) | 2013-11-05 | 2022-07-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US20200338022A1 (en) | 2019-01-07 | 2020-10-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| MX388666B (es) * | 2013-11-05 | 2025-03-20 | Antecip Bioventures Ii Llc | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
| US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| SG11201701645WA (en) * | 2014-09-14 | 2017-04-27 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
| CA2968371C (en) | 2014-11-21 | 2020-08-18 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| WO2017165845A1 (en) * | 2016-03-24 | 2017-09-28 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| CR20210368A (es) * | 2019-01-07 | 2021-12-10 | Antecip Bioventures Ii Llc | Combinación de dextrometorfano y bupropión para el tratamiento de depresión |
| US20230225995A1 (en) * | 2019-01-07 | 2023-07-20 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| CA3179048A1 (en) * | 2020-03-30 | 2021-10-07 | Antecip Bioventures Ii Llc | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| WO2022119981A1 (en) | 2020-12-01 | 2022-06-09 | Antecip Bioventures Ii Llc | Bupropion and dextromethrophan for reduction of suicide risk in depression patients |
| JP2024503114A (ja) * | 2021-01-18 | 2024-01-24 | アンテシップ バイオベンチャーズ トゥー エルエルシー | 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ |
| CN112999350A (zh) * | 2021-02-23 | 2021-06-22 | 北京斯利安药业有限公司 | 一种药物组合物、复方制剂及其制备方法与应用 |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| CN118785900A (zh) * | 2022-06-30 | 2024-10-15 | 艾克萨姆治疗公司 | 包含安非他酮和半胱氨酸的药物组合物 |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350756A (en) * | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| JP2001527554A (ja) * | 1997-05-07 | 2001-12-25 | アルゴス ファーマシューティカル コーポレーション | 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法 |
| US6207674B1 (en) * | 1999-12-22 | 2001-03-27 | Richard A. Smith | Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants |
| US6780871B2 (en) * | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| MX2008009947A (es) * | 2006-02-03 | 2008-10-20 | Avanir Pharmaceuticals | Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos. |
| WO2009006194A1 (en) * | 2007-06-28 | 2009-01-08 | Avanir Pharmaceuticals | Pharmaceutical compositions for the treatment of involuntary emotional expression disorder |
| WO2012118562A1 (en) | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US20130274282A1 (en) * | 2012-04-16 | 2013-10-17 | Herriot Tabuteau | Compositions and methods comprising celecoxib or related compounds and dextromethorphan |
| MX388666B (es) * | 2013-11-05 | 2025-03-20 | Antecip Bioventures Ii Llc | Composiciones y metodos que comprenden bupropion o compuestos relacionados y dextrometorfano |
-
2014
- 2014-11-05 MX MX2020004075A patent/MX388666B/es unknown
- 2014-11-05 CN CN202111061795.3A patent/CN113750099A/zh active Pending
- 2014-11-05 WO PCT/US2014/064184 patent/WO2015069809A1/en not_active Ceased
- 2014-11-05 EP EP21191390.0A patent/EP3981403A1/en active Pending
- 2014-11-05 CA CA2929415A patent/CA2929415C/en active Active
- 2014-11-05 SG SG11201603391XA patent/SG11201603391XA/en unknown
- 2014-11-05 CN CN201910649198.9A patent/CN110327338A/zh active Pending
- 2014-11-05 KR KR1020237034772A patent/KR20230148385A/ko active Pending
- 2014-11-05 SG SG10201911808QA patent/SG10201911808QA/en unknown
- 2014-11-05 SG SG10201911816XA patent/SG10201911816XA/en unknown
- 2014-11-05 CN CN202111061803.4A patent/CN113797205A/zh active Pending
- 2014-11-05 SG SG10201810888XA patent/SG10201810888XA/en unknown
- 2014-11-05 CA CA3175703A patent/CA3175703C/en active Active
- 2014-11-05 IL IL298972A patent/IL298972A/en unknown
- 2014-11-05 NZ NZ758428A patent/NZ758428A/en unknown
- 2014-11-05 MX MX2016005867A patent/MX373330B/es active IP Right Grant
- 2014-11-05 EP EP21191393.4A patent/EP3981404A1/en active Pending
- 2014-11-05 CA CA3154845A patent/CA3154845C/en active Active
- 2014-11-05 CA CA3256217A patent/CA3256217A1/en active Pending
- 2014-11-05 KR KR1020167013970A patent/KR102264179B1/ko active Active
- 2014-11-05 KR KR1020227013910A patent/KR102603013B1/ko active Active
- 2014-11-05 JP JP2016552474A patent/JP6605485B2/ja active Active
- 2014-11-05 MY MYPI2016701609A patent/MY179696A/en unknown
- 2014-11-05 EP EP14859589.5A patent/EP3065742A4/en active Pending
- 2014-11-05 CN CN201910649207.4A patent/CN110279682A/zh active Pending
- 2014-11-05 CN CN201480072191.0A patent/CN106163522A/zh active Pending
- 2014-11-05 CN CN202111061009.XA patent/CN113750098A/zh active Pending
- 2014-11-05 KR KR1020217016618A patent/KR20210068157A/ko not_active Ceased
- 2014-11-05 CN CN201910649199.3A patent/CN110251517A/zh active Pending
- 2014-11-05 AU AU2014346807A patent/AU2014346807B2/en active Active
-
2016
- 2016-05-04 MX MX2021015234A patent/MX2021015234A/es unknown
- 2016-05-05 IL IL245504A patent/IL245504B/en active IP Right Grant
-
2018
- 2018-05-23 AU AU2018203638A patent/AU2018203638C1/en active Active
-
2019
- 2019-09-23 AU AU2019236614A patent/AU2019236614C1/en active Active
- 2019-10-16 JP JP2019189318A patent/JP6927601B2/ja active Active
- 2019-12-04 AU AU2019275593A patent/AU2019275593B2/en active Active
-
2021
- 2021-04-23 AU AU2021202497A patent/AU2021202497B2/en active Active
- 2021-06-07 IL IL283760A patent/IL283760B2/en unknown
- 2021-07-29 JP JP2021124094A patent/JP2021169527A/ja active Pending
-
2023
- 2023-06-01 AU AU2023203438A patent/AU2023203438B2/en active Active
- 2023-07-27 JP JP2023122146A patent/JP2023129646A/ja active Pending
-
2025
- 2025-09-12 AU AU2025230795A patent/AU2025230795A1/en active Pending
- 2025-09-26 JP JP2025160293A patent/JP2025175199A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373330B (es) | Composiciones y métodos que comprenden bupropion o compuestos relacionados y dextrometorfano. | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
| MX375254B (es) | Una composición antimicrobiana farmacéutica o veterinaria intramamaria que comprende un poliéter ionóforo, o un uso de la misma para tratar mastitis. | |
| BR112015029462A8 (pt) | Inibidores de quinase | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX383254B (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| MX2015003564A (es) | Composiciones y metodos de uso de un compuesto de control de inapetencia. | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| UA113859C2 (xx) | Похідні спіротієнопіранпіперидину як антагоністи рецептора orl-1 для їх застосування при лікуванні алкогольної залежності та зловживання алкоголем | |
| EA201690445A1 (ru) | Лечение рака | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| BR112016014099A2 (pt) | método de tratamento de feridas | |
| WO2014153505A3 (en) | Treatment of chemotherapy-induced peripheral neuropathy | |
| EA201501177A1 (ru) | Фармацевтические композиции | |
| HK1228779A1 (zh) | 包含安非他酮或相关化合物和右美沙芬的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |